Phase I Study Of P-Glycoprotein (P-gp) Mediated Drug Interactions Between Lenalidomide (LEN) and Quinidine Or Temsirolimus

被引：1
|
作者：
Chen, Nianhang
Weiss, Daniel
Reyes, Josephine
Liu, Liangang
Kasserra, Claudia
Wang, Xiaomin
Zhou, Simon
Kumar, Gondi
Weiss, Lilia
Palmisano, Maria
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.5395.5395
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5395
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats
    K. Kishore Kumar
    Leena Priyanka
    K. Gnananath
    P. Ravindra Babu
    S. Sujatha
    European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40 : 267 - 276
  • [42] Evaluation of drug interactions with P-glycoprotein in drug discovery:: In vitro assessment of the potential for drug-drug interactions with P-glycoprotein
    Hochman, JH
    Yamazaki, M
    Ohe, T
    Lin, JH
    CURRENT DRUG METABOLISM, 2002, 3 (03) : 257 - 273
  • [43] Erratum to: No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers
    Nianhang Chen
    Daniel Weiss
    Josephine Reyes
    Liangang Liu
    Claudia Kasserra
    Xiaomin Wang
    Simon Zhou
    Gondi Kumar
    Lilia Weiss
    Maria Palmisano
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 659 - 660
  • [44] A study of the novel P-glycoprotein (P-gp) antagonist, XR9576 in combination with vinorelbine.
    Abraham, J
    Edgerly, M
    Wilson, R
    Medina, W
    Hermonstine, L
    Rutt, A
    Bakke, S
    Robey, R
    Grem, J
    Bates, S
    Fojo, T
    Chen, C
    Dwyer, A
    Goldspiel, B
    Van Tellingen, O
    Norris, D
    Steiner, J
    Waterfall, J
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3739S - 3740S
  • [45] Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats
    Kumar, K. Kishore
    Priyanka, Leena
    Gnananath, K.
    Babu, P. Ravindra
    Sujatha, S.
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2015, 40 (03) : 267 - 276
  • [46] Influence of P-glycoprotein (P-gp) induction on the pharmacokinetics of risperidone and paliperidone in mouse brain
    Holthoewer, D.
    Hiemke, C.
    Schmitt, U.
    PHARMACOPSYCHIATRY, 2009, 42 (05) : 223 - 223
  • [47] Mibefradil is a potent inhibitor of both CYP3A and P-glycoprotein (P-gp).
    Wandel, C
    Kim, RB
    Guengerich, FP
    Wood, AJJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 124 - 124
  • [48] Relevance of p-glycoprotein (P-gp) and CD34 expression in childhood AML
    vanderHeuvelEibrink, MM
    Boekhorst, PAW
    Schoester, M
    Pieters, R
    vanderHolt, B
    Sonneveld, P
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1339 - 1339
  • [49] BSP loaded as a high dose is partially excreted into bile by P-glycoprotein (P-GP).
    Takikawa, H
    Sano, N
    Kitaura, K
    Fukumura, S
    Aiso, M
    Uegaki, S
    Akimoto, K
    Sato, A
    Yamanaka, M
    GASTROENTEROLOGY, 1997, 112 (04) : A1395 - A1395
  • [50] Analogues of the Lignan Pinoresinol as Novel Lead Compounds for P-glycoprotein (P-gp) Inhibitors
    Laiolo, Jeronimo
    Tomasic, Tihomir
    Vera, D. Mariano A.
    Gonzalez, Maria L.
    Lanza, Priscila A.
    Gancedo, Samanta N.
    Hodnik, Ziga
    Masic, Lucija Peterlin
    Kikelj, Danijel
    Carpinella, Maria C.
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (12): : 1186 - 1192
12345